Christiaan H. Bangma

Christiaan H. Bangma's AcademicInfluence.com Rankings

Medical

#3020

World Rank

#3471

Historical Rank

Urology

#26

World Rank

#27

Historical Rank

medical Degrees

Christiaan H. Bangma

Philosophy

#8717

World Rank

#12148

Historical Rank

Logic

#5745

World Rank

#7170

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Christiaan H. Bangma's Degrees

Doctorate Medicine Erasmus University Rotterdam
PhD Urology Erasmus University Rotterdam

Why Is Christiaan H. Bangma Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christiaan H. Bangma's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Screening and prostate-cancer mortality in a randomized European study. (2009) (3849)
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up (2014) (1283)
Prostate-cancer mortality at 11 years of follow-up. (2012) (1245)
Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. (2015) (579)
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. (2013) (489)
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. (2011) (437)
Quality-of-life effects of prostate-specific antigen screening. (2012) (393)
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (2019) (308)
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. (2009) (290)
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. (2016) (287)
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. (2012) (283)
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer (2012) (278)
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. (2019) (273)
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. (2010) (268)
Exosomes as biomarker treasure chests for prostate cancer. (2011) (262)
Prospective validation of active surveillance in prostate cancer: the PRIAS study. (2007) (234)
Anxiety and distress during active surveillance for early prostate cancer (2009) (231)
The mutational landscape of prostate cancer. (2013) (230)
The prostate health index selectively identifies clinically significant prostate cancer. (2015) (228)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (221)
Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer (2015) (220)
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). (2009) (213)
Defining a standard set of patient-centered outcomes for men with localized prostate cancer. (2014) (195)
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. (2010) (194)
Overdiagnosis and overtreatment of early detected prostate cancer (2007) (190)
Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. (2017) (185)
Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. (2019) (182)
Short‐term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study (2010) (175)
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. (2012) (172)
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. (2008) (163)
Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. (2014) (163)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Diagnostic value of OCT3/4 for pre‐invasive and invasive testicular germ cell tumours (2005) (156)
A new and highly prognostic system to discern T1 bladder cancer substage. (2012) (154)
Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. (2012) (152)
Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. (2006) (148)
Outcomes of initially expectantly managed patients with low or intermediate risk screen‐detected localized prostate cancer (2012) (148)
Active surveillance for prostate cancer: a narrative review of clinical guidelines (2016) (141)
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. (2012) (127)
Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. (2015) (123)
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). (2019) (121)
Timing of curative treatment for prostate cancer: a systematic review. (2013) (116)
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. (2013) (115)
The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. (1995) (115)
Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. (2015) (115)
Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. (2015) (114)
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. (2012) (112)
The European Randomized Study of Screening for Prostate Cancer (ERSPC). (2010) (108)
Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer (2010) (106)
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC (2010) (105)
Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. (2009) (103)
Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. (2005) (99)
Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. (2012) (94)
The FGFR3 mutation is related to favorable pT1 bladder cancer. (2009) (94)
The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. (1995) (91)
Does PSA velocity predict prostate cancer in pre-screened populations? (2006) (89)
Validation of the urogenital distress inventory (UDI‐6) and incontinence impact questionnaire (IIQ‐7) in a Dutch population (2015) (88)
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. (2006) (87)
Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. (2014) (85)
False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up (2010) (85)
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. (2010) (84)
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. (2010) (84)
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results (2013) (83)
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. (2013) (83)
The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date (2018) (82)
Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer (2017) (82)
Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. (2009) (80)
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. (2012) (78)
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. (1995) (77)
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. (1998) (76)
Do anxiety and distress increase during active surveillance for low risk prostate cancer? (2010) (76)
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer (2017) (74)
A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels (2015) (74)
The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. (1997) (73)
Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment (2013) (73)
Risk‐stratification based on magnetic resonance imaging and prostate‐specific antigen density may reduce unnecessary follow‐up biopsy procedures in men on active surveillance for low‐risk prostate cancer (2017) (72)
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues (2010) (71)
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population (1998) (71)
Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening (2004) (68)
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. (2010) (68)
Prediction of prostate cancer in unscreened men: external validation of a risk calculator. (2011) (67)
Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. (2005) (66)
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. (1994) (66)
A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine (2013) (66)
Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer (2012) (65)
A methylation assay for the detection of non‐muscle‐invasive bladder cancer (NMIBC) recurrences in voided urine (2012) (64)
Men's preferences for prostate cancer screening: a discrete choice experiment (2013) (64)
A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. (2019) (63)
Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. (2016) (62)
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. (1997) (62)
Bladder cancer biomarkers and their role in surveillance and screening (2009) (62)
Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis (2018) (62)
Establishing normal reference ranges for prostate volume change with age in the population‐based Krimpen‐study: Prediction of future prostate volume in individual men (2007) (61)
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). (2009) (61)
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer (2008) (61)
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. (2013) (61)
Disease‐specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy (2015) (60)
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. (2009) (60)
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. (2010) (60)
Is magnetic resonance imaging‐targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low‐risk prostate cancer? A systematic review and meta‐analysis (2018) (60)
Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. (2020) (59)
Expert consensus document: Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure (2017) (57)
Age-specific reference ranges for prostate-specific antigen. (1994) (57)
Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. (2016) (57)
Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. (2005) (56)
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour (2009) (55)
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. (2013) (55)
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study (2016) (54)
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. (2019) (54)
Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. (2005) (54)
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. (2011) (54)
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. (2008) (53)
Orgasmic dysfunction after open radical prostatectomy: clinical correlates and prognostic factors. (2010) (52)
Pathological stage review is indicated in primary pT1 bladder cancer (2009) (52)
The Long-Term Relationship between a Real Change in Prostate Volume and a Significant Change in Lower Urinary Tract Symptom Severity in Population-Based Men: The Krimpen Study (2008) (51)
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. (2013) (51)
Sexual function with localized prostate cancer: active surveillance vs radical therapy (2012) (51)
The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancer (2004) (50)
Screening and early detection of prostate cancer (2000) (50)
Prostate cancer screening in Europe and Asia (2016) (50)
CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. (2010) (50)
Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 men (2009) (48)
Fertility potential in men with a history of congenital undescended testes: a long‐term follow‐up study (2013) (48)
Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts (2011) (46)
Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). (2013) (46)
Prostate specific antigen in a community‐based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism (1995) (46)
Histopathological characteristics of lymph node metastases predict cancer‐specific survival in node‐positive prostate cancer (2008) (44)
Transrectal ultrasonic volumetry of the prostate: In vivo comparison of different methods (1996) (43)
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. (2013) (42)
Positive predictive value of prostate biopsy indicated by prostate‐specific‐antigen‐based prostate cancer screening: trends over time in a European randomized trial * (2012) (41)
2127 P2PSA IN COMBINATION WITH TOTAL PSA AND FREE PSA IMPROVES DIAGNOSTIC ACCURACY IN PROSTATE CANCER DETECTION (2010) (41)
Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract (2006) (41)
Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. (2011) (41)
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. (2012) (40)
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. (2008) (39)
Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. (1998) (39)
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. (2007) (38)
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. (2008) (38)
Discordant performance of assays for free and total prostate‐specific antigen in relation to the early detection of prostate cancer (2001) (38)
Towards an optimal interval for prostate cancer screening. (2012) (38)
Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease (2018) (38)
Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI (2020) (36)
Long‐term follow‐up of T1 high‐grade bladder cancer after intravesical bacille Calmette‐Guérin treatment (2011) (35)
The measurement properties of the five‐item International Index of Erectile Function (IIEF‐5): a Dutch validation study (2015) (35)
Compliance with biopsy recommendations of a prostate cancer risk calculator (2012) (35)
Fertility potential in a cohort of 65 men with previously acquired undescended testes. (2014) (35)
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening (2015) (35)
The value of EZH2, p27kip1, BMI‐1 and MIB‐1 on biopsy specimens with low‐risk prostate cancer in selecting men with significant prostate cancer at prostatectomy (2009) (34)
Active surveillance for low-risk prostate cancer. (2013) (33)
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). (2010) (32)
Prostate-specific antigen as a screening test. The Netherlands experience. (1997) (31)
High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience. (2012) (31)
Predictive models in diagnosing indolent cancer (2009) (30)
Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. (2008) (29)
Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome (2018) (28)
Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. (2019) (28)
Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy (2009) (28)
Summary statement on screening for prostate cancer in Europe (2018) (27)
QUALITY OF LIFE EFFECTS OF INTERMITTENT AND CONTINUOUS HORMONAL THERAPY BY CYPROTERONE ACETATE (CPA) FOR METASTATIC PROSTATE CANCER (2008) (26)
Free and total prostate-specific antigen in a screened population. (1997) (26)
Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study (2012) (26)
Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume (2016) (25)
Defining and predicting indolent and low risk prostate cancer. (2012) (25)
Different PSA assays lead to detection of prostate cancers with identical histological features. (2002) (25)
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study (2021) (24)
Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection. (2017) (24)
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression (2011) (24)
To be screened or not to be screened? Modeling the consequences of PSA screening for the individual (2012) (24)
Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer (2017) (24)
Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study (2018) (24)
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial (2014) (23)
Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy (2010) (23)
Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients (2020) (23)
Watchful waiting in prostate cancer: review and policy proposals (2003) (22)
Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary? (2020) (22)
Higher free testosterone level is associated with faster visual processing and more flanker interference in older men (2009) (22)
A Multi-Center, Multi-Vendor Study to Evaluate the Generalizability of a Radiomics Model for Classifying Prostate cancer: High Grade vs. Low Grade (2021) (21)
Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. (2015) (21)
Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? (2017) (21)
Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator. (2010) (21)
Radical prostatectomy versus deferred treatment for localised prostate cancer. (2020) (20)
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. (2010) (20)
Sonography, CT, and MRI of giant cavernous hemangioma of the kidney: correlation with pathologic findings. (2004) (20)
Papillary Necrosis Associated with the HIV Protease Inhibitor Indinavir (2001) (20)
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. (2009) (19)
Can non‐malignant biopsy features identify men at increased risk of biopsy‐detectable prostate cancer at re‐screening after 4 years? (2008) (19)
The implementation of screening for prostate cancer (2010) (19)
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial (2013) (18)
Disease-specific mortality may underestimate the total effect of prostate cancer screening (2010) (17)
Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy (2020) (17)
Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens (2019) (17)
Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients. (2006) (17)
Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer. (2019) (16)
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years. (2005) (16)
Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy. (1995) (16)
Volume adjustment for intermediate prostate-specific antigen values in a screening population. (1995) (16)
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study (2009) (16)
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. (2020) (16)
Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes (2018) (15)
Introducing PIONEER: a project to harness big data in prostate cancer research (2020) (15)
Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam. (2015) (15)
Classification of Clinically Significant Prostate Cancer on Multi-Parametric MRI: A Validation Study Comparing Deep Learning and Radiomics (2021) (14)
Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens (2020) (14)
Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors (2013) (14)
Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy (2019) (14)
Early Diagnosis and Treatment of Localized Prostate Cancer (2001) (14)
Effects of luminal oxalate or calcium oxalate on renal tubular cells in culture (2005) (14)
Prevention and screening (2002) (14)
Identifying and characterizing “escapes”—men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam) (2011) (14)
Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7 (2018) (13)
Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. (1995) (13)
Complications of initial prostate biopsy in a European randomized screening trial. (2012) (12)
Prostate-specific antigen: its clinical use and application in screening for prostate cancer. (1995) (12)
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation (2013) (12)
Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer (2015) (12)
Additional benefit of using a risk‐based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (2017) (11)
The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis (2012) (11)
The Role of Ultrasonography (2013) (11)
Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality. (2011) (11)
Active surveillance: oncologic outcome (2013) (11)
PSA and the Detection of Prostate Cancer After 2005. Part I (2006) (11)
Prostate MRI, with or without targeted biopsy and standard biopsy for detecting prostate cancer: A Cochrane systematic review and meta-analysis (2019) (11)
Analysis of the video motion tracking system “Kinovea” to assess surgical movements during robot‐assisted radical prostatectomy (2020) (11)
Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS) (2015) (10)
Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. (2017) (10)
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up. (2011) (10)
Intraoperative assessment and reporting of radical prostatectomy specimens to guide nerve‐sparing surgery in prostate cancer patients (NeuroSAFE) (2020) (10)
Blood and serum substances for markers of prostate cancer (2000) (9)
Clinicopathological characteristics of glomeruloid architecture in prostate cancer (2020) (9)
958 Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer (2016) (9)
Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer. (1997) (9)
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. (1995) (9)
Comparison of two assays for human kallikrein 2. (2003) (8)
Burns to the perineum and genitals — management, results and function of the thermally injured perineum in a 5-year-review (1995) (8)
Urothelial Cancer Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX 2 , TBX 3 , GATA 2 , and ZIC 4 as pTa-Specific Prognostic Markers (2012) (8)
Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer? (2019) (7)
Prostate-specific antigen screening can be beneficial to younger and at-risk men (2013) (7)
20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers (2009) (7)
Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction. (2007) (7)
1847 [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY (2010) (7)
ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS (2009) (7)
A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men. (2022) (7)
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. (2017) (7)
Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). (2019) (7)
Bladder volume measurements with a limited number of fixed ultrasound beams. (2004) (6)
Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam? (2015) (6)
Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients (2021) (6)
WORLDWIDE VARIATION IN DETERMINANTS FOR INCLUSION AND FOLLOW‐UP IN ACTIVE SURVEILLANCE FOR LOW‐RISK PROSTATE CANCER: RESULTS OF THE MOVEMBER FOUNDATION’S GLOBAL ACTION PLAN PROSTATE CANCER ACTIVE SURVEILLANCE (GAP3) INITIATIVE: PD28‐05 (2017) (6)
Training novice robot surgeons: Proctoring provides same results as simulator-generated guidance (2020) (5)
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes (2018) (5)
How Often is Biopsy Necessary in Patients with Prostate Cancer on Active Surveillance? (2016) (5)
Should prostate-specific antigen screening be offered to asymptomatic men? (2010) (5)
Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method. (2013) (5)
Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients (2021) (5)
354 Focal therapy in prostate cancer – international multidisciplinary consensus on trial design (2014) (5)
Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients (2021) (4)
Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning. (2013) (4)
1027 OUTCOME OF SCREEN-DETECTED PROSTATE CANCER PATIENTS WHO COULD HAVE BEEN CONSIDERED FOR ACTIVE SURVEILLANCE (2007) (4)
OVERALL VERSUS DISEASE-SPECIFIC SURVIVAL OF SCREEN- DETECTED PROSTATE CANCER PATIENTS WHO WERE INITIALLY MANAGED EXPECTANTLY (2008) (4)
PSA-density based patient selection for MRI-targeted prostate biopsy could reduce unnecessary biopsy procedures in men on active surveillance for low-grade prostate cancer (2017) (4)
Reply from Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy—Thou Shall Think Twice. Eur Urol 2012;61:1115–7: Considerations for Prostate Biopsy Decisions (2012) (4)
284 HOW TO SCREEN FOR PROSTATE CANCER AFTER 2008? PSA AS A BIOPSY INDICATOR, PART II (2009) (4)
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research (2020) (4)
1016 CYSTOSCOPY REVISITED AS THE GOLD STANDARD FOR DETECTION OF BLADDER CANCER RECURRENCES: DIAGNOSTIC REVIEW BIAS IN A PROSPECTIVE RANDOMISED TRIAL (2009) (4)
Risk-based selection for active surveillance: Results of the Movember Foundation’s Global Action Plan prostate cancer active surveillance (GAP3) initiative (2017) (4)
Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer (2020) (4)
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. (2021) (4)
1036 Active surveillance for low risk prostate cancer: The study protocol of the Movember Global Action Plan 3 (GAP3) project (2015) (4)
[MRI/US-fusion for targeted prostate biopsy]. (2014) (4)
Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance (2017) (4)
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status (2019) (3)
Adherence to active surveillance protocols for low-risk prostate cancer: Results of the Movember Foundation’s global action plan prostate cancer active surveillance (GAP3) initiative (2017) (3)
MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer (2017) (3)
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. (2013) (3)
Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma (2016) (3)
Structured robot-assisted surgery training curriculum for residents in Urology and impact on future surgical activity (2020) (3)
[Variability of values of prostate-specific antigen determined with 6 methods]. (1994) (3)
NeuroSAFE in radical prostatectomy increases the rate of nerve‐sparing surgery without affecting oncological outcome (2022) (3)
PD60-04 PROSTATE MRI, WITH OR WITHOUT TARGETED BIOPSY, AND STANDARD BIOPSY FOR DETECTING PROSTATE CANCER: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS (2019) (3)
PD34-04 FREQUENCY OF PSA TESTING IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER. (2015) (3)
Follow-up strategy and survival for five common cancers: A meta-analysis. (2022) (3)
Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial. (2019) (3)
Individual and Population-Based Screening (2017) (2)
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative (2022) (2)
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative (2022) (2)
2055 PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS (2013) (2)
Value of magnetic resonance imaging in population-based prostate cancer screening: Comparison of 3 biopsy strategies in the 5th screening round of the ERSPC Rotterdam (2017) (2)
Disease-specific and patient-reported outcomes under active surveillance (2015) (2)
680 Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: Results of a randomized trial (2013) (2)
A 16-year Follow-up of the European Randomized study of Screening for Prostate Cancer (2019) (2)
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database (2021) (2)
Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring? (2020) (2)
Sexual function following treatment of localised prostate cancer with HDR-Ir-192 brachytherapy combined with external beam radiotherapy (2006) (2)
Free serum prostate-specific antigen and screening for prostate cancer. (1996) (2)
Abstract 4023: Genome-wide analysis of CpG island methylation identified OTX1, OSR1 and ONECUT2 as biomarkers for recurrent bladder cancer detection in voided urine (2012) (2)
Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. (2020) (2)
Words of wisdom. Re: effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. (2008) (2)
124 FEASIBILITY STUDY OF POPULATION BASED SCREENING FOR BLADDER CANCER WITH URINARY MOLECULAR MARKERS (BLUP) (WWW.BLU-PROJECT.ORG) (2009) (2)
Identifying the relationship between postoperative urinary continence and residual urethra stump measurements in robot assisted radical prostatectomy patients (2020) (2)
Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study (2021) (2)
PROSPECTIVE PROTOCOL BASED ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: SHORT-TERM RESULTS OF 500 PATIENTS IN THE PRIAS STUDY (2009) (2)
THE USE OF -2proPSA AND BPSA IN PROSTATE CANCER DETECTION: EXTERNAL CROSS-VALIDATION OF A PREDICTIVE MODEL (2008) (1)
Algorithms based on PSA, free PSA, DRE result and prostate volume increase specificity of prostate cancer screening (2003) (1)
27 Protocol based versus non-protocol based discontinuation in the Prostate cancer Research International: Active Surveillance (PRIAS) study (2014) (1)
Platinum Priority – Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol 2009;55:9–11 (2009) (1)
Active Surveillance: The European Experience (2012) (1)
MP-2.17: Feasibility Study of Population-Based Screening for Bladder Cancer with Urinary Molecular Markers (BLUP): (www.blu-project.org) (2008) (1)
PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer (2020) (1)
1026 NOMOGRAM USE FOR THE PREDICTION OF INDOLENT PROSTATE CANCER IN MEN SELECTED FOR ACTIVE SURVEILLANCE (2007) (1)
5 Disease-specific survival of men with screen-detected prostate cancer: Comparison of first round vs second round cancers in an European randomized screening trial (2013) (1)
[Early detection of prostate cancer--recommendations after 13 years of follow-up in the European randomised study]. (2015) (1)
Imaging , Diagnosis , Prognosis A 3-Plex Methylation Assay Combined with the FGFR 3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine (2013) (1)
Re: Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured as age 44 to 50 years. (2007) (1)
PSA and the Detection of Prostate Cancer After 2005. Part II: Ways Out of the PSA Dilemma? (2006) (1)
17 VALIDATION OF THE ERSPC RISK CALCULATOR IN A CLINICAL SETTING (2011) (1)
Screening for prostate cancer (2000) (1)
[Presence of prostate cancer, but absence of active treatment]. (2019) (1)
611 RULE-BASED VERSUS PROBABILISTIC SELECTION FOR ACTIVE SURVEILLANCE FOR PROSTATE CANCER AND OUTCOMES AFTER RADICAL PROSTATECTOMY (2010) (1)
Re: Automated prostate volume determination with ultrasonographic imaging. (1996) (1)
How common is PSA screening in elderly men with limited life expectancies? (2007) (1)
Bladder carcinogenesis, in search of clues and genes. (2006) (1)
645 LONG-TERM FOLLOW-UP FOR PRIMARY T1 HIGH-GRADE BLADDER CANCER. DOES BCG REALLY PREVENT PROGRESSION? (2009) (1)
393 HOW TO HANDLE A MINOR FOCUS OF HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (HG-PIN) ON PROSTATE NEEDLE BIOPSY IN A SCREENING SETTING (2009) (1)
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database (2022) (1)
A Prospective, Observational, Multicentre Study Concerning Nontechnical Skills in Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy (2020) (1)
2060 INFECTIOUS COMPLICATIONS AND HOSPITAL ADMISSIONS AFTER PROSTATE BIOPSY IN A EUROPEAN RANDOMIZED TRIAL (2012) (1)
672 IMPACT OF SUB-STAGE AND PATHOLOGY REVIEW ON THE CLINICAL OUTCOME OF PT1 BLADDER CANCER (2009) (1)
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database (2022) (1)
Active surveillance and radical prostatectomy. (2011) (1)
606 HOW TO SCREEN FOR PROSTATE CANCER (PC) IN MEN PRESENTING WITH LOW PSA (< 3.0 NG/ML) – DO WE HAVE TO FIND ALL CANCERS? (2007) (1)
Multivariable risk-based patient selection for targeted prostate biopsy in case of suspicious Magnetic Resonance Imaging could reduce unnecessary biopsy procedures (2016) (1)
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database (2022) (1)
1 Screening for prostate cancer: Results of the Rotterdam section of the European Randomized study of Screening for Prostate Cancer (ERSPC) (2013) (1)
124 OUTCOMES OF MEN DIAGNOSED WITH SCREEN-DETECTED PROSTATE CANCER INITIALLY WITHHOLDING RADICAL TREATMENT (2010) (1)
800 SHOULD MEN AGE 55 – 74 PRESENTING WITH PSA < 3.0 NG/ML BE BIOPSIED TO DIAGNOSE PROSTATE CANCER (PC)? (2007) (1)
PSA level changes over time in men with an initial PSA level of ≤4 ng/ml (2006) (1)
THE CLINICAL IMPACT OF THE PSA ASSAY WHO CALIBRATION ON PROSTATE BIOPSY RATES AND PROSTATE CANCER DETECTION (2008) (1)
982 EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)1 IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION (2011) (1)
The future of prostate cancer research: bringing data together, looking back and forward (2018) (1)
Magnetic Resonance Imaging-based Monitoring in Active Surveillance: Are We Ready To Jump on the Bandwagon? (2022) (1)
Routine use of Prostate Health Index (PHI) reduces majority of unnecessary prostatic biopsies in Asian men: A prospective study in 2795 men seen at Urology clinics (2018) (1)
A multi-centre evaluation of the role of Prostate Health Index (PHI) in regions with different prevalences of prostate cancer: A different reference range is needed for European and Asian (2018) (1)
Prostate specific antigen and ultrasonography in detection and follow-up of prostate carcinoma (1995) (1)
1 A 3-plex methylation assay combined with the FGFR 3 mutation assay sensitively detects recurrent bladder cancer in voided urine Running title : Urine biomarkers for recurrent bladder cancer detection (2013) (1)
Understanding Active Surveillance. A new treatment option for PSA detected low risk prostate cancer. (2009) (1)
SERUM PSA LEVELS, NUMBER OF PROSTATE BIOPSIES AND NUMBER AND CHARACTERISTICS OF PROSTATE CANCERS DETECTED IN THREE CONSECUTIVE SCREENING VISITS USING A PSA BASED BIOPSY INDICATION (2008) (1)
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results (2013) (1)
770 Improved patient selection for MRI-targeted prostate biopsy after negative random biopsy with the Rotterdam Prostate Cancer Risk Calculator (2015) (1)
70 oral: Clinical Outcome of Interstitial High Dose Rate (HDR) Brachytherapy + External Beam Radiotherapy (EBRT) for Early Stage Prostate Cancer (2009) (1)
[Mass screening for detection of prostatic carcinoma]. (2000) (0)
526 OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA ≥20 NG/ML OR BIOPSY GLEASON SCORE ≥8) WITH RADICAL PROSTATECTOMY AS INITIAL STEP: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS (2009) (0)
PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients. (2009) (0)
MP50-02 OUTCOMES AFTER INTRODUCING INTRAOPERATIVE FROZEN SECTIONS IN ROBOT-ASSISTED RADICAL PROSTATECTOMY (2021) (0)
1033 Rule-based versus probabilistic selection for active surveillance for prostate cancer (2015) (0)
A survey on postoperative results analysis and surgical video review of robot-assisted radical prostatectomy: How do they do it? (2020) (0)
Active surveillance of men younger than 60: Assessment of differences in discontinuation and treatment choice in the Movember GAP3 Consortium (2019) (0)
SIMILAR HIGH‐GRADE PROSTATE CANCER DETECTION BY SEXTANT BIOPSY, 12‐CORE TRUS BIOPSY AND MRI‐TARGETED BIOPSY IN THE 5TH SCREENING ROUND OF THE ERSPC ROTTERDAM: MP33‐01 (2017) (0)
Randomized Prostate Cancer Screening Trial (ERSPC):complete follow-up, improve test characteristics, identify non-aggressive cancers (2006) (0)
MP48-04 ACTIVE SURVEILLANCE OF MEN YOUNGER THAN 60: ASSESSMENT OF DIFFERENCES IN DISCONTINUATION AND TREATMENT CHOICE IN THE MOVEMBER GAP3 CONSORTIUM (2019) (0)
Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer (2021) (0)
Clinical and experimental aspects of urological tumors (1988) (0)
PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007 (2009) (0)
851 Will men with very low PSA values accept a long screening interval (2014) (0)
THE PREDICTIVE VALUE OF EZH2, BMI-1, P27KIP1 AND MIB-1 ON PROSTATE CANCER BIOPSY SPECIMENS OF MEN WITH LOW-RISK DISEASE (2009) (0)
447 Outcomes of a European bladder cancer screening program using home hematuria testing and molecular markers (2012) (0)
Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for metastatic castration-resistant prostate cancer (2018) (0)
PD35-04 COULD DIFFERENCES IN TREATMENT BETWEEN TRIAL ARMS EXPLAIN THE REDUCTION IN PROSTATE CANCER MORTALITY IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER? (2019) (0)
PD17-01 UPFRONT MRI IS THE NEW STANDARD, HAVE CONFIRMATORY BIOPSIES BECOME OBSOLETE? (2021) (0)
Discontinuation of active surveillance of men with GG2 PCa: Assessment of 14 centres in 8 countries in the Movember GAP3 consortium (2019) (0)
Evaluating active surveillance as treatment option for low risk prostate cancer: What is the golden standard and how do they compare? A large retrospective cohort study (2016) (0)
Reply from Authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice. Eur Urol 2013;63:788–9: 5-Alpha Reductase Inhibitors in Prostate Cancer (2013) (0)
PD08-04 VALIDATION OF A RISK CALCULATOR PREDICTING BIOPSY OUTCOME IN PROSTATE CANCER TREATED WITH ACTIVE SURVEILLANCE (2016) (0)
Eight year patient reported outcome data of the first 150 Dutch men on active surveillance in the Prostate cancer Research International Active Surveillance study (PRIAS) (2019) (0)
PSA based screening reduces the rate of prostate cancer death by 20 (2009) (0)
METASTASES AND DEATH AFTER 15 YEAR OF FOLLOW‐UP IN MEN WITH SCREEN‐DETECTED LOW‐RISK PROSTATE CANCER TREATED WITH PROTOCOL BASED ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY OR RADIOTHERAPY: PD03‐01 (2017) (0)
[-2]pro-prostate specific antigen as an aid in prostate biopsy. (2012) (0)
Continence after introducing NeuroSAFE in radical prostatectomy (2022) (0)
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. (2023) (0)
The Role of Conservative Policies in the Treatment of Prostate Cancer (2008) (0)
137 EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION (2010) (0)
829 STANDARD REPEAT BIOPSIES DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: PREDICTORS FOR UPGRADING OR UPSTAGING (2009) (0)
20 DISEASE-SPECIFIC SURVIVAL IN MEN WITH INTERVAL CANCERS COMPARED TO MEN WITH CANCERS IN THE CONTROL ARM: LONG-TERM RESULTS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) (2011) (0)
A 2-arm pseudo-randomized multicenter (MR PROPER) trial: MRI-directed pathway outperforms TRUS-directed pathway in prostate cancer diagnosis following upfront risk stratification (2021) (0)
Re: Prostate Cancer Stem Cells: A New Target for Therapy (2008) (0)
545 PEPTIDE RECEPTOR TARGETING IS SUPERIOR TO METABOLIC TARGETING FOR IN VIVO IMAGING OF HUMAN PROSTATE CANCER XENOGRAFTS (2010) (0)
Abstract 549: A urine based assay to select patients for initial cystoscopy (2015) (0)
52 COMPARISON OF MOLECULAR MARKERS, SUB-STAGE AND THE EORTC RISK-SCORE TO PREDICT CLINICAL OUTCOME OF PT1 BLADDER CANCER (2010) (0)
PD62-12 COMPARISON OF DIFFERENT BIOPSY SCHEDULES AMONG MEN ON ACTIVE SURVEILLANCE: ANALYSIS OF THE GAP3 GLOBAL CONSORTIUM DATABASE (2020) (0)
MRI/ultrasound-fusion for targeted prostate biopsy (2014) (0)
A first step towards a global nomogram to predict disease progression for men on active surveillance (2020) (0)
392 THE PREDICTIVE VALUE OF EZH2, P27KIP1 AND MIB-1 ON PROSTATE CANCER BIOPSY SPECIMENS IN MEN WITH LOW-RISK DISEASE (2009) (0)
MP86-18 MRI TARGETED BIOPSY MAY ENHANCE DIAGNOSTIC PERFORMANCE OF SIGNIFICANT PROSTATE CANCER DETECTION COMPARED TO STANDARD TRANSRECTAL ULTRASOUND GUIDED BIOPSY: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015) (0)
170 20-25% LOWER PSA VALUES WITH PSA TEST STANDARDIZATION TO THE WHO REFERENCE MATERIAL: SUMMARY OF 4 STUDIES IN 1100 PATIENTS (2009) (0)
EP-1109 POSTOPERATIVE RADIOTHERAPY IN PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY: CLINICAL OUTCOME (2012) (0)
The relation between baseline PSA, cancer detection and PC death, long-term data from ERSPC (2019) (0)
Men on active surveillance without cancer on biopsy are less likely to reclassify (2018) (0)
1921 VALIDATION OF THE PROSTATE CANCER RISK CALCULATOR IN A CLINICAL SETTING (2011) (0)
A first step towards a global nomogram to predict disease progression for men on active surveillance (2020) (0)
497 Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam (2016) (0)
Prostate Cancer Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing : New Insights from the European Randomized Study of Screening for Prostate Cancer (2015) (0)
184 A URINE-BASED METHYLATION ASSAY FOR THE DETECTION OF RECURRENCES DURING FOLLOW-UP OF NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS (2011) (0)
P95 Planned interviews about sexuality to men with genitourinary cancer (2010) (0)
Tumourigenesis and disease course in superficial bladder cancer (2008) (0)
LB7 Classification of healthy bladder tissue and tumour bladder tissue by raman spectroscopy (2004) (0)
401 PRE-OPERATIVE PREDICTORS OF HIGH-GRADE PROSTATE CANCER IN BIOPSY AND RADICAL PROSTATECTOMY SPECIMENS (2007) (0)
Robot-Assisted Radical Prostatectomy: A Survey on the Influence of Postoperative Results Analysis and Surgical Video Review on Postoperative Complications and Functional Results. (2020) (0)
Potential new treatment for patients with bladder cancer with a high risk of progression to invasive disease (2019) (0)
P19 UROTHELIAL TUMOURS: BASIC RESEARCHThursday, 19 March, 09.15-10.45, Room A6308 THE FGFR3 MUTATION IS RELATED TO FAVORABLE PT1 BLADDER CANCER (2009) (0)
20-25% Lower Psa Values With Psa Test Standardization To the Who Reference Material: Summary of 4 Studies in 1100 Patients (2009) (0)
149 Pathological review of prostate biopsy specimens affects eligibility for active surveillance programs (2012) (0)
949 Long-term quality of life outcomes after active surveillance or curative treatment for prostate cancer (2016) (0)
1340 PROTOCOL-BASED REASONS TO SWITCH TO RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE PREDICT FOR UNFAVOURABLE OUTCOME (2012) (0)
Platinum Priority – Collaborative Review – Prostate Cancer (2013) (0)
Large cribriform growth pattern identifies cribriform Gleason score 3+4=7 prostate cancer patients at high risk for recurrence and metastasis (2018) (0)
Abstract 3012: Genome-wide analysis of CpG island methylation in bladder cancer identifies novel biomarkers for diagnosis, prediction of progression and survival (2011) (0)
1087 Radical prostatectomy results after initial active surveillance (2012) (0)
217 Structured reporting of multiparametric MRI in detecting prostate cancer: Accuracy and inter-observer variability (2013) (0)
P074 Stereotactic body radiotherapy (SBRT) with a focal boost to the visible MRI tumor as monotherapy for intermediate stage prostate cancer: Early results (2012) (0)
1779 REPEAT PROSTATE BIOPSIES IN MEN WITH LOW RISK PROSTATE CANCER IN A PROSPECTIVE ACTIVE SURVEILLANCE PROGRAM: FINDINGS AND CONSEQUENCES (2011) (0)
1013 PREDICTING FAVOURABLE PATHOLOGICAL OUTCOME IN PATIENTS WITH CLINICAL HIGH RISK PROSTATE CANCER. A NOVEL NOMOGRAM BASED ON A MULTI-INSTITUTIONAL ANALYSIS (2010) (0)
Prostate-specific antigen as a screening test : The Netherlands experience : Prostate-specific antigen: the best prostatic tumor marker (1997) (0)
959 PROSPECTIVE PROTOCOL BASED ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: SHORT-TERM RESULTS OF 500 PATIENTS IN THE PRIAS STUDY (2009) (0)
Structured robot assisted surgery training curriculum for residents in Urology and impact on future surgical activity (2020) (0)
MICROSATELLITE INSTABILITY AND MUTATION ANALYSIS OF CANDIDATE GENES IN UROTHELIAL CELL (2006) (0)
711 poster HDR BRACHYTHERAPY AS MONOTHERAPY FOR EARLY STAGE PROSTATE CANCER: ACUTE TOXICITY (2011) (0)
996 LIVING WITH UNTREATED PROSTATE CANCER: THE IMPACT OF ACTIVE SURVEILLANCE ON QUALITY OF LIFE (2012) (0)
MP38-13 HAS ACTIVE SURVEILLANCE OF PROSTATE CANCER BECOME SAFER? LESSONS LEARNED FROM A GLOBAL CLINICAL REGISTRY: MOVEMBER GAP3 CONSORTIUM (2023) (0)
Re: Modern Imaging in Prostate Cancer: Do We Treat Patients or Their Scans? (2022) (0)
THE ERSPC VERSUS THE PROTECT STUDY: OUTCOMES AFTER ACTIVE SURVEILLANCE COMPARED TO SURGERY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER.: PD55‐04 (2017) (0)
FALSE-NEGATIVE PROSTATE BIOPSY FOR ADENOCARCINOMA: INCIDENCE AND FOLLOW-UP IN A HIGH-RISK SCREENED POPULATION (2008) (0)
Comparison of different biopsy schedules among men on active surveillance: Analysis of the GAP3 global consortium database (2020) (0)
Implementing Gallium-68-PSMA PET/CT in multidisciplinary teams: The impact on treatment of patients with biochemical recurrence after primary treatment with curative intent (2016) (0)
MP62-10 OUTCOME IN MEN CONTINUING ACTIVE SURVEILLANCE DESPITE PROTOCOL ADVICE TO DISCONTINUE (2014) (0)
Outcomes after introducing intraoperative NeuroSAFE technique in robot-assisted radical prostatectomy (2021) (0)
Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy (2017) (0)
1757: How to Screen for Prostate Cancer in 2007 - Detection and Characteristics in men age 55 - 74, in men with PSA Levels Less than 3 ng/ml, 4 and 8 Years after the Initial Screening (Erspc Rotterdam) (2007) (0)
1005 AN FGFR3 MUTATION IN CELLS OBTAINED FROM VOIDED URINE IS A STRONG PREDICTOR OF RECURRENT BLADDER CANCER (2009) (0)
PROSTATE CANCER (PC) IN MEN PRESENTING WITH PSA <3.0 NG/ML – DETECTION AT RE-SCREENING AND AS INTERVAL CANCERS DURING A 12-YEAR PERIOD (2008) (0)
In response to DRS. Aarnink and Wijkstra (1995) (0)
Salvage radiotherapy after radical prostatectomy (2018) (0)
Non-invasive diagnosis of recurrent bladder cancer (2006) (0)
Editorial Comment: Biological Variation of Total, Free and Percent Free Serum Prostate Specific Antigen Levels in Screening Volunteers (1997) (0)
Influence of cribriform/intraductal growth and percentage Gleason grade 4 on clinical outcome of men with biopsy Gleason score 3+4=7 prostate cancer (2016) (0)
53 Fertility in men with acquired undescended testis, where spontaneous testicular descent was awaited until puberty: Spontaneous descend versus orchiopexy (2012) (0)
2033 DISEASE-SPECIFIC SURVIVAL IN MEN WITH INTERVAL CANCERS COMPARED TO MEN WITH CANCERS IN THE CONTROL ARM: LONG-TERM RESULTS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC)-ROTTERDAM (2011) (0)
822 Are early repeat biopsies associated with an increased risk of complications (2012) (0)
PD64-02 THE RELATION BETWEEN BASELINE PSA, CANCER DETECTION AND PC DEATH, LONG-TERM DATA FROM ERSPC (2019) (0)
MP62-01 UNCHANGED NEGATIVE PROSTATE MPMRI DURING ACTIVE SURVEILLANCE. DO WE NEED TO BIOPSY AND FOLLOW-UP? (2021) (0)
MP43-05 UPFRONT MRI IS THE NEW STANDARD, HAVE CONFIRMATORY BIOPSIES BECOME OBSOLETE? (2022) (0)
Comment on: A polymorphism of the osteopontin gene is related to urinary calcium stones Bing Gao et al (2006) (0)
Gentherapie in de urologie (2001) (0)
Re: A polymorphism of the osteopontin gene is related to urinary calcium stones (2006) (0)
602 OPTIMALIZATION OF NON-MUSCLE-INVASIVE BLADDER CANCER RECURRENCE DETECTION USING A URINE- BASED FGFR3 MUTATION ASSAY (2011) (0)
1086 Outcomes of initially expectantly managed patients with low- or intermediate-risk screen-detected localized prostate cancer (2012) (0)
Outcome of Multimodality Treatment of Clinically Locally Advanced Prostate Cancer With Radical Prostatectomy As Initial Step: a Multi-institutional Outcome Study of 895 Patients (2009) (0)
The Importance of Positive Section Margins in Patients With High Risk Prostate Cancer Treated With Radical Prostatectomy (2009) (0)
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting (2023) (0)
181 HOW MANY CONSECUTIVE 3-MONTHLY PSA MEASUREMENTS ARE NEEDED IN MEN WITH EARLY PROSTATE CANCER ON ACTIVE SURVEILLANCE TO CALCULATE A REPRESENTATIVE PSA DOUBLING TIME? (2009) (0)
521 THE ROLE OF ADJUVANT TREATMENT STRATEGIES AFTER SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER (2009) (0)
MISSING A PROSTATE CANCER LESION DURING HISTOLOGICAL EXAMINATION OF PROSTATE BIOPSY: CHARACTERISTICS AND FOLLOW-UP IN A SCREENED COHORT (2009) (0)
[Analysis of the microsatellite instability gene mutation in the urothelial tumor of the upper urinary tract]. (2005) (0)
195 IMPACT OF SUB-STAGE ON THE CLINICAL OUTCOME OF PT1 BLADDER CANCER (2010) (0)
POD-02.09 Living with Untreated Prostate Cancer: The Impact on Quality of Life of Active Surveillance (2011) (0)
Words of wisdom. Re: Prostate cancer stem cells: a new target for therapy. Maitland NJ, Collins AT. (2008) (0)
Abstract 1932: Cationic amphiphilic drugs as a potential new treatment option for patients with high risk non-muscle invasive bladder cancer (2019) (0)
Identification of pathologic factors associated with intraoperative positive surgical margins at NeuroSAFE for clinical decision-making on nerve-sparing surgery (2022) (0)
1925 SCREENING FOR PROSTATE CANCER OUTCOMES OF A PILOT STUDY AFTER 16 YEARS OF FOLLOW-UP (2012) (0)
Reply from authors re: Brant A. Inman, Michael R. Abern. Interpreting a study on bladder cancer screening. Eur Urol 2013;64:48-50: the goal of cancer screening: early evaluation of screening for bladder cancer. (2013) (0)
542 YOUNG PATIENTS (≤40 YEARS) PRESENTING WITH BLADDER CANCER, WHAT CAN WE EXPECT (2011) (0)
OC-0062: High-dose-rate HDR boost for localized prostate cancer decreases long term rectum toxicity (2016) (0)
989 PROSTATE CANCER DISEASE PROGRESSION AND MORTALITY AFTER RADICAL PROSTATECTOMY OR EXTERNAL BEAM RADIOTHERAPY: RESULTS FROM THE ERSPC, SECTION ROTTERDAM (2012) (0)
POD-07.06 Inter-observer Variability in the Interpretation of HistoScanning™ Characterisation of Prostate Cancer (2011) (0)
A MUTATION DETECTED IN THE FIBROBLAST GROWTH FACTOR RECEPTOR-3 IN CELLS OBTAINED FROM VOIDED URINE IS A STRONG PREDICTOR OF RECURRENT BLADDER CANCER (2009) (0)
1137: Indomethacin Inhibits the Production and Expression of Hyaluronan by Regenerating Renal Tubular Cells During Wound Healing which is Accompanied by Decreased Levels of Calcium Oxalate Crystal Binding (2004) (0)
Prostate Cancer: Localized VIModerated Poster 451552 PREDICTING FAVOURABLE PATHOLOGICAL OUTCOME IN PATIENTS WITH CLINICAL HIGH RISK PROSTATE CANCER. A NOVEL NOMOGRAM BASED ON A MULTI-INSTITUTIONAL ANALYSIS (2010) (0)
Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator (2023) (0)
1461 RADICAL PROSTATECTOMY FOR LOW-RISK PROSTATE CANCER AFTER INITIAL ACTIVE SURVEILLANCE (2011) (0)
The use of multiple video assessment methods to determine the influence of surgical skill on potency and continency in patients after robot-assisted radical prostatectomy (2019) (0)
PD13-04 PROSTATE CANCER SPECIFIC MORTALITY IN THE ERSPC TRIAL: WHAT IS THE ROLE OF SCREENING RESULT AND ADHERENCE (2021) (0)
The prevalence and progression of lower urinary tract symptoms in an ageing population – results from the European Randomized study of Screening for Prostate Cancer (Rotterdam) (2017) (0)
Outcome of multimodality treatment of high-risk localized prostate cancer (cT3-4 OR PSA >= 20 ng/ml OR biopsy Gleason score >= 8) with radical prostatectomy as initial step: a multi-institutional outcome study of 1413 patients (2009) (0)
Bellardita, L. (2017). Setting an agenda for assessment of health-related quality of life among men with prostate cancer on active surveillance: a consensus paper from a European School of Oncology task (2016) (0)
51 MOLECULAR MARKERS SHOW DIFFERENCES IN BIOLOGICAL POTENTIAL PER GRADE CATEGORY FOR THE WHO 1973 AND 2004 CLASSIFICATION SYSTEMS: A LARGE MULTI-CENTER STUDY WITH CENTRAL PATHOLOGY REVIEW IN NON-MUSCLE INVASIVE BLADDER CANCER (2010) (0)
Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer. (2023) (0)
MP59-03 A URINE-BASED MUTATION-METHYLATION ASSAY FOR THE SURVEILLANCE OF HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS (2022) (0)
OUTCOME OF MULTIMODALITY TREATMENT WITH RADICAL PROSTATECTOMY AS INITIAL STEP FOR PROSTATE CANCER WITH PSA >20 NG/ML : A MULTI-INSTITUTIONAL OUTCOME STUDY OF 801 PATIENTS (2009) (0)
Large cribriform growth in Gleason 3+4=7 prostate cancer (2018) (0)
187 Active surveillance activities in Europe for prostate cancer (2009) (0)
837 Improved diagnostic urine assay to select patients for initial cystoscopy (2015) (0)
MP48-02 DISCONTINUATION OF ACTIVE SURVEILLANCE OF MEN WITH GG2 PCA: ASSESSMENT OF 14 CENTRES IN 8 COUNTRIES IN THE MOVEMBER GAP3 CONSORTIUM (2019) (0)
Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial (2021) (0)
398 NO PROSTATE CANCER DETECTED DESPITE A HIGH-CALCULATED CANCER DETECTION PROBABILITY BASED ON PRE-BIOPSY INFORMATION (2007) (0)
Unchanged negative prostate mpMRI during active surveillance, is it still necessary to biopsy and follow-up? (2021) (0)
Validation of cAMP phosphodiesterase-4D7 (PDE4D7) for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes. (2017) (0)
314Sexual function of men following treatment of localised prostate cancer with HDR-IR-192 brachytherapy combined with external beam radiotherapy (2005) (0)
1932 SCREENING FOR PROSTATE CANCER: RESULTS OF THE ROTTERDAM SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) (2013) (0)
An MRI guided active surveillance strategy. Can the PRECISE score exclude reclassification? (2021) (0)
ONCOLOGICAL OUTCOME AND TREATMENT-RELATED TOXICITY IN PATIENTS WITH LOCALISED PROSTATE CANCER FOLLOWING HDR-IR-192 BRACHYTHERAPY COMBINED WITH EXTERNAL BEAM RADIOTHERAPY (2006) (0)
969 DISEASE SPECIFIC MORTALITY MAY UNDERESTIMATE THE TOTAL EFFECT OF PROSTATE CANCER SCREENING (2010) (0)
Upfront MRI is the new standard, have confirmatory biopsies become obsolete? (2021) (0)
328 Genome-wide analysis of CpG island methylation in bladder cancer identifies novel biomarkers for diagnosis and prediction of progression (2012) (0)
[Post mortem semen acquisition: not without 'informed consent']. (2003) (0)
ANXIETY IN MEN ON ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER (2008) (0)
RESEARCH — MEN ’ S SEXUAL HEALTH Orgasmic Dysfunction After Open Radical Prostatectomy : Clinical Correlates and Prognostic (2010) (0)
1014 REPEAT PROSTATE BIOPSIES IN MEN WITH LOW RISK PROSTATE CANCER IN A PROSPECTIVE ACTIVE SURVEILLANCE PROGRAM: FINDINGS AND CONSEQUENCES (2011) (0)
Intraoperative NeuroSAFE in robot-assisted radical prostatectomy increases nerve-sparing surgery without affecting oncological outcome (2022) (0)
Urologists’ Opinion on Active Surveillance: USA Versus the Netherlands (2012) (0)
In Reply: RE (1998) (0)
Individual and Mass Screening (2012) (0)
364 COMPLICATIONS ON REPEAT VERSUS INITIAL PROSTATE BIOPSY IN A RANDOMIZED SCREENING TRIAL (2012) (0)
115 Gleason score reclassification of men with classical Gleason score ≤6 who eventually died of prostate cancer in the ERSPC Rotterdam (2015) (0)
Prostate cancer specific mortality in the ERSPC trial: What is the role of screening result and adherence (2021) (0)
Intraoperative NeuroSAFE enables more frequent nerve-sparing radical prostatectomies (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christiaan H. Bangma?

Christiaan H. Bangma is affiliated with the following schools:

University of Pennsylvania
Aarhus University

Christiaan H. Bangma's Academic­Influence.com Rankings

Christiaan H. Bangma's Degrees

Why Is Christiaan H. Bangma Influential?

Christiaan H. Bangma's Published Works

Published Works

What Schools Are Affiliated With Christiaan H. Bangma?

Christiaan H. Bangma's AcademicInfluence.com Rankings